Lantern Pharma (NASDAQ: LTRN) announced it will host an investor, analyst and shareholder briefing on April 9, 2026, at 8:30 a.m. Eastern, featuring a live demonstration of withZeta.ai, described as the first multi-agentic AI co-scientist for rare cancer drug discovery, development and clinical trial design. The webcast will highlight the platform’s capabilities, commercial architecture, competitive positioning and revenue strategy, alongside an overview of the rare cancer market opportunity and Lantern’s growth roadmap, with participation from CEO Panna Sharma and Chief Scientific Officer Kishor Bhatia.
The briefing underscores Lantern Pharma’s commitment to leveraging its proprietary AI and machine learning platform, RADR(R), which utilizes over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms. According to the company, this technology helps solve billion-dollar problems in oncology drug development, generating medicines at dramatically reduced costs and accelerated timelines. On average, Lantern’s drug programs have advanced from initial AI insights to first-in-human clinical trials in 2–3 years at approximately $1.0–2.5 million per program.
The withZeta.ai platform represents a significant advancement in AI-driven drug discovery, aiming to streamline the process for rare cancers, which often lack effective treatments. The company’s pipeline includes a Phase 2 clinical program and multiple planned Phase 1b/2a clinical trials, with a focus on solid tumors, blood cancers, and an antibody-drug conjugate (ADC) program. Additionally, Lantern has established a wholly-owned subsidiary, Starlight Therapeutics, to concentrate on CNS and brain cancer therapies.
The rare cancer market opportunity is substantial, with Lantern’s pipeline estimated to have a combined annual market potential of over $15 billion USD. The April 9 briefing will provide investors with insights into how withZeta.ai is positioned to capture this market. For those interested, the full press release is available at https://ibn.fm/UXTr3.
Lantern Pharma continues to attract attention from the investment community, and the upcoming demo could be a catalyst for further interest. The company’s AI-driven approach represents a paradigm shift in oncology drug development, potentially reducing the time and cost required to bring new therapies to patients. As the event approaches, stakeholders will be watching closely for details on the platform’s commercial viability and revenue potential.
